CL
CARM

CSS LLC’s Carisma Therapeutics CARM Stock Holding History

CSS LLC’s Portfolio CARM Stock Details CARM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-60
Closed -$186 – 906
2023
Q1 		$186 Sell
60
-2,490
-98% -$23.7K ﹤0.01% 722
2022
Q4 		$31.1K Buy
2,550
+55
+2% +$578 ﹤0.01% 762
2022
Q3 		$21K Buy
+2,495
New +$34K ﹤0.01% 929

Other funds holding CARM

TOTUOP
Trustees of The University of Pennsylvania Philaldelphia, Pennsylvania $297M AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

CSS LLC's CARM Position: Q3 2023 in Review

CSS LLC sold out of Carisma Therapeutics (CARM) in Q3 2023, closing a stake of 10,485 shares — an estimated $92K sold.

CSS LLC first reported a position in CARM in Q3 2022 and held it in 4 quarters. The position peaked at $159K in Q4 2022. 58 funds tracked by Wall St. Rank hold CARM as of Q3 2023.

  • CSS LLC reported no remaining Carisma Therapeutics position as of Q3 2023 after selling out during the quarter.
  • CSS LLC sold 10,485 Carisma Therapeutics shares in Q3 2023, an estimated $92K.
  • CSS LLC first reported a position in Carisma Therapeutics in Q3 2022 and held it in 4 quarters.
  • CSS LLC's Carisma Therapeutics position peaked at $159K in Q4 2022.
  • 58 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q3 2023.

Based on CSS LLC's 13F filing for Q3 2023, filed 14 Nov 2023.